Free Trial
→ 2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (From Darwin) (Ad)

15 Healthcare Stocks that Analysts Love in a Post-Pandemic World - 12 of 15

Slide 12
Back to 11
Continue to 13
 
Back to 11
Continue to 13
 

Teva Pharmaceutical Industries (NYSE:TEVA)

Consensus Rating
Moderate Buy
Rating Score
2.8
Ratings Breakdown
7 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$19.67 (18.7% Upside)

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries logoTeva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
10/23/2024BarclaysBoost Price TargetOverweight ➝ Overweight$22.00 ➝ $25.00
10/21/2024JPMorgan Chase & Co.Boost Price TargetNeutral ➝ Neutral$16.00 ➝ $18.00
9/3/2024UBS GroupBoost Price TargetBuy ➝ Buy$24.00 ➝ $26.00
8/1/2024BarclaysBoost Price TargetOverweight ➝ Overweight$21.00 ➝ $22.00
7/10/2024UBS GroupBoost Price TargetBuy ➝ Buy$22.00 ➝ $24.00
7/10/2024ArgusUpgradeHold ➝ Buy$20.00
6/27/2024Jefferies Financial GroupBoost Price TargetBuy ➝ Buy$19.00 ➝ $23.00
6/5/2024BarclaysBoost Price TargetOverweight ➝ Overweight$20.00 ➝ $21.00
5/30/2024Bank of AmericaBoost Price TargetBuy ➝ Buy$18.00 ➝ $21.00
5/13/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$19.00 ➝ $20.00
Slide 12
Back to 11
Continue to 13
 

Has Trump Finally Gone Too Far? (Ad)

Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.

Register For The Webinar To Discover

More From MarketBeat
Bill Gates’ is about to mint millionaires (again) with Stargate.
This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...
Brownstone Research | Sponsored
7 of the Best Options for Investing $5,000 in 2025
Part of managing your money is taking calculated risks to help your money work for you. That means, whether yo...
MarketBeat
Musk’s new company could top a trillion?
The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...
Paradigm Press | Sponsored
20 "Past Their Prime" Stocks to Dump From Your Portfolio
Did you know the S&P 500 as we know it today does not look anything close to what it looked like 30 years ...
MarketBeat
24/7 Automated Profits in Crypto
The 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...
Crypto Swap Profits | Sponsored
7 Oversold Stocks That Could Be Setting Up for a Rally
In 2024, investors are still wrestling with uncertainty. Will there be rate cuts, and what will they mean for ...
MarketBeat